TY - JOUR T1 - Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 1479 LP - 1480 DO - 10.1136/annrheumdis-2022-222628 VL - 81 IS - 10 AU - Koichi Takeda AU - Noriko Yanagitani Y1 - 2022/10/01 UR - http://ard.bmj.com/content/81/10/1479.abstract N2 - Rheumatic immune-related adverse events (irAEs) occur in approximately 10% of patients receiving immune checkpoint inhibitors (ICIs).1 Here, we report a case of psoriatic arthritis (PsA) that occurred during ICI treatment for lung cancer and was successfully treated with guselkumab.A 64-year-old man with stage IIIC lung cancer was treated with definitive concurrent chemoradiotherapy followed by six cycles of weekly carboplatin and paclitaxel. He was then started on biweekly durvalumab (antiprogrammed death-ligand 1 antibody) monotherapy. After the sixth cycle of durvalumab administration, he developed shoulder pain, a skin rash, and nail changes. Due to the high possibility of irAEs, durvalumab was discontinued and prednisolone 20 mg/day was started. However, his symptoms continued to worsen; therefore, he was referred to our department of oncorheumatology.Before starting durvalumab, he had never experienced such skin rashes or nail changes and had no family history of any autoimmune disease. On physical examination, tender entheses on the shoulders, distal … ER -